Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN FE 1 20 versus NORETHIN 1 50M 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN FE 1 20 versus NORETHIN 1 50M 21.
LOESTRIN FE 1/20 vs NORETHIN 1/50M-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive consisting of ethinyl estradiol and norethindrone acetate. Inhibits gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
One tablet (norethindrone acetate 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by one ferrous fumarate tablet (75 mg) orally once daily for 7 days.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: 6-9 hours (terminal). Ethinyl estradiol: 13-27 hours (terminal, mean 16 hours). Steady-state reached within 5-7 days.
Terminal elimination half-life: 5-14 hours (mean ~8h). Clinical context: Steady-state achieved after 4-5 days; dosing interval 24 hours maintains therapeutic levels.
Norethindrone: 50-60% renal (as metabolites), 20-30% fecal. Ethinyl estradiol: 40-50% renal (as glucuronide conjugates), 30-40% fecal (as sulfate conjugates).
Renal: 50-60% as metabolites; Fecal: 30-40% (via biliary); Less than 5% unchanged in urine.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive